AnaptysBio (NASDAQ:ANAB) Price Target Raised to $79.00

AnaptysBio (NASDAQ:ANAB) had its price objective lifted by Barclays from $78.00 to $79.00 in a report issued on Wednesday morning,Benzinga reports. The firm currently has an overweight rating on the biotechnology company’s stock.

Other equities analysts also recently issued research reports about the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AnaptysBio in a report on Wednesday, January 21st. HC Wainwright increased their price objective on shares of AnaptysBio from $51.00 to $66.00 and gave the stock a “buy” rating in a research note on Wednesday. Truist Financial raised their price objective on shares of AnaptysBio from $20.00 to $36.00 and gave the company a “hold” rating in a research report on Monday, November 10th. Stifel Nicolaus lowered their target price on shares of AnaptysBio from $80.00 to $56.00 and set a “buy” rating on the stock in a research note on Thursday, December 11th. Finally, UBS Group started coverage on shares of AnaptysBio in a report on Wednesday, January 7th. They issued a “buy” rating and a $70.00 target price for the company. Nine research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $73.44.

AnaptysBio Stock Down 3.3%

NASDAQ ANAB opened at $55.41 on Wednesday. AnaptysBio has a 52 week low of $15.32 and a 52 week high of $63.47. The company has a market capitalization of $1.59 billion, a P/E ratio of -106.56 and a beta of 0.32. The stock’s 50-day moving average price is $50.27 and its 200-day moving average price is $39.03.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings data on Monday, March 9th. The biotechnology company reported $1.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.89 by $0.69. The company had revenue of $108.25 million during the quarter, compared to the consensus estimate of $87.09 million. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 5.64%. Research analysts anticipate that AnaptysBio will post -6.08 EPS for the current year.

AnaptysBio declared that its board has approved a share buyback program on Friday, November 21st that allows the company to repurchase $100.00 million in outstanding shares. This repurchase authorization allows the biotechnology company to repurchase up to 9.6% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s management believes its shares are undervalued.

Insiders Place Their Bets

In other AnaptysBio news, CFO Dennis Mulroy sold 15,725 shares of the stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $44.85, for a total transaction of $705,266.25. Following the completion of the sale, the chief financial officer directly owned 9,401 shares of the company’s stock, valued at $421,634.85. This trade represents a 62.58% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Daniel Faga sold 15,309 shares of AnaptysBio stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $43.26, for a total transaction of $662,267.34. Following the sale, the chief executive officer owned 458,139 shares in the company, valued at approximately $19,819,093.14. The trade was a 3.23% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 156,280 shares of company stock valued at $7,254,939. 33.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On AnaptysBio

Several institutional investors have recently bought and sold shares of the stock. Smartleaf Asset Management LLC increased its holdings in AnaptysBio by 5,864.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 835 shares of the biotechnology company’s stock valued at $40,000 after acquiring an additional 821 shares during the last quarter. Larson Financial Group LLC boosted its holdings in shares of AnaptysBio by 54.6% during the 3rd quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 473 shares during the last quarter. Bessemer Group Inc. boosted its holdings in shares of AnaptysBio by 950.0% during the 3rd quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 1,292 shares during the last quarter. Tower Research Capital LLC TRC grew its position in shares of AnaptysBio by 175.0% during the second quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 1,377 shares in the last quarter. Finally, Osaic Holdings Inc. grew its position in shares of AnaptysBio by 11,630.0% during the second quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company’s stock valued at $52,000 after purchasing an additional 2,326 shares in the last quarter.

AnaptysBio News Roundup

Here are the key news stories impacting AnaptysBio this week:

• Positive Sentiment: Stifel Nicolaus raised its price target sharply to $85 and kept a buy rating — a sizable upside vs. recent levels that likely boosted investor demand. Stifel raises PT to $85
• Positive Sentiment: Coverage noting a profitability turnaround and continued progress collecting Jemperli royalties supports a higher valuation narrative for ANAB. This fundamental story likely underpins recent buying interest. Assessing AnaptysBio valuation after profitability turnaround
• Positive Sentiment: ANAB hit a new 12?month high following analyst upgrades, which can attract momentum and technical buying. ANAB hits new 12?month high on analyst upgrade
• Negative Sentiment: HC Wainwright issued a mixed set of estimate changes: it lowered near?term FY2026 and Q1/Q2 EPS forecasts (worse near?term profitability) even as it raised several multi?year estimates; the negative near?term revisions could pressure sentiment despite the firm’s buy rating and $66 target. HC Wainwright estimate changes (MarketBeat summary)
• Neutral Sentiment: Short?interest entries in recent reports are inconsistent/zero (showing NaN increases), indicating unreliable short?interest data — not a clear driver of today’s move. (No reliable link provided in the filings.)

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.